Ciba-Geigy
Executive Summary
Signs three-year research agreement with SIBIA for the development of central nervous system treatments using SIBIA's cloned human excitatory amino acid (EAA) receptor technology, Ciba announces Sept. 16. The Swiss firm will purchase a $5 mil. equity stake in La Jolla, Calif.-based SIBIA and provide research support, milestone payments and royalties on any product sales resulting from the collaboration. Possible disease targets include stroke, epilepsy and Alzheimer's.